Peptide Comparison
DihexavsPinealon
Angiotensin IV-derived oligopeptide that potentiates hepatocyte growth factor to drive synaptogenesis and cognitive enhancement with extraordinary potency
Neuroprotective tripeptide bioregulator (Glu-Asp-Arg) that penetrates the DNA major groove to epigenetically regulate serotonin synthesis, preserve dendritic spine architecture, and activate endogenous antioxidant defenses against age-related neurodegeneration
At a Glance
Quick
comparison
Dose Range
Dihexa
8–20 mg
Pinealon
1–2 mg
Frequency
Dihexa
Once daily
Pinealon
Multiple times daily
Administration
Dihexa
Oral (capsule/tablet)
Pinealon
Oral (capsule/tablet)
Cycle Length
Dihexa
4-6 weeks
Pinealon
2-4 weeks
Onset Speed
Dihexa
Moderate (1-2 weeks)
Pinealon
Gradual (3-4 weeks)
Evidence Level
Dihexa
Preclinical only — animal and cell-culture studies; no human trials
Pinealon
Emerging preclinical
Efficacy
Benefit
ratings
Cognitive
Healing & Recovery
Anti-Aging
Brain Protection
Mood Support
Memory Preservation
Technical Data
Compound
specifications
Dihexa
Molecular Formula
C27H44N4O5
Molecular Weight
504.7 g/mol
Half-Life
~12 days (following IV administration in rats)
Bioavailability
Orally active and blood-brain barrier permeable — specific oral bioavailability percentage not published
CAS Number
1401708-83-5
Pinealon
Molecular Formula
C15H26N6O8
Molecular Weight
418.4 g/mol
Half-Life
Short plasma half-life typical of tripeptides (minutes to low hours); biological effects persist for weeks to months through epigenetic gene regulation mechanisms
Bioavailability
Orally bioavailable as a dipeptide/tripeptide absorbed by intestinal peptide transporters (PepT1/SLC15A1); crosses the blood-brain barrier; rapid cellular uptake due to ultra-short peptide structure
CAS Number
175175-23-2
Protocols
Dosing
tiers
Dihexa
Pinealon
Applications
Best
suited for
Dihexa
Age-Related Cognitive Decline
Dihexa directly addresses the synaptic loss that underlies age-related cognitive decline by building new functional synaptic connections in the hippocampus. Animal studies demonstrate restored spatial learning in aged rats, making it a compelling candidate for combating memory loss associated with aging.
Neuroplasticity Enhancement
Unlike nootropics that work through neurotransmitter modulation, dihexa drives physical neuroplasticity — the formation of new dendritic spines and synapses. This makes it ideal for individuals looking to enhance their brain's capacity for learning and adaptation at a structural level.
Neurodegenerative Disease Research
Preclinical evidence in APP/PS1 Alzheimer's mice and scopolamine-induced amnesia models positions dihexa as a leading research compound for neurodegenerative disease. It is patented for potential use in Alzheimer's and Parkinson's diseases, with ongoing interest from the research community.
Advanced Nootropic Stacking
Dihexa's unique mechanism (HGF/c-Met potentiation) is complementary to most other nootropic mechanisms, making it an excellent addition to advanced cognitive enhancement protocols when combined with choline donors, racetams, or adaptogens.
Pinealon
Neuroprotection against age-related cognitive decline and neurodegeneration
Pinealon is particularly effective for individuals focused on neuroprotection against age-related cognitive decline and neurodegeneration. Research supports its use in this area.
Supporting serotonin production in aging individuals with diminished serotonergic function
Pinealon is particularly effective for individuals focused on supporting serotonin production in aging individuals with diminished serotonergic function. Research supports its use in this area.
Bioregulatory approach to brain aging using Khavinson peptide methodology
Pinealon is particularly effective for individuals focused on bioregulatory approach to brain aging using khavinson peptide methodology. Research supports its use in this area.
Complementing other neuroprotective peptides in comprehensive anti-aging protocols
Pinealon is particularly effective for individuals focused on complementing other neuroprotective peptides in comprehensive anti-aging protocols. Research supports its use in this area.
Safety Profile
Side
effects
Dihexa
Common
- Headache
- Vivid dreams or altered sleep patterns
- Emotional sensitivity
- Mild fatigue during adjustment
Uncommon
- Gastrointestinal discomfort
Serious
- Theoretical oncogenic risk from c-Met activation
Pinealon
Common
- Mild drowsiness
- Mild headache
- Vivid dreams
- Mild gastrointestinal discomfort
Uncommon
- Transient mood changes
- Changes in sleep patterns
Serious
- Theoretical serotonergic interaction
Research Status
Safety
& evidence
Dihexa
Evidence Level
Preclinical only — animal and cell-culture studies; no human trials
FDA Status
Research compound
Safety Overview
Dihexa has demonstrated a favorable safety profile in published animal studies, with no reported tumorigenic effects or organ toxicity at cognitive-enhancing doses. However, the compound has not undergone formal human clinical trials, and long-term safety data does not exist. The primary theoretical safety concern is sustained activation of the HGF/c-Met proto-oncogenic pathway, which could theoretically promote tumor initiation or growth. The extremely long half-life (~12 days) raises additional concerns about compound accumulation with chronic daily dosing. Anecdotal reports from the nootropics community generally describe good tolerability at doses of 5-20 mg daily, with headaches and vivid dreams as the most commonly reported effects.
Contraindications
- xKnown or suspected malignancy — c-Met/HGF pathway activation may promote tumor growth
- xPregnancy and breastfeeding — no safety data available
- xHistory of cancer, particularly HGF/c-Met-driven tumors (hepatocellular, gastric, lung)
- xSevere hepatic impairment
Pinealon
Evidence Level
Emerging preclinical
FDA Status
Research compound
Safety Overview
Pinealon shows excellent safety profile in Russian clinical trials with no serious adverse events at therapeutic intramuscular doses. Well-tolerated with minimal injection site reactions; mild headache reported in <3% of subjects during initiation phase. No systemic toxicity in repeat-dose animal studies; no mutagenicity or carcinogenicity observed. Long half-life reduces dosing frequency; epigenetic changes documented are regulatory (H3K9 acetylation patterns) without genetic mutations.
Contraindications
- xKnown hypersensitivity to Pinealon or its constituent amino acids (glutamic acid, aspartic acid, arginine)
- xPregnancy and breastfeeding — insufficient safety data in reproductive studies
- xConcurrent use of serotonergic medications (SSRIs, MAOIs) without medical supervision — theoretical risk of additive serotonergic effects
- xAutoimmune conditions affecting the CNS — immunomodulatory peptide effects may be unpredictable
Decision Guide
Which is
right for you?
Choose Dihexa if...
- Cognitive enhancement and memory consolidation in age-related decline
- Supporting neuroplasticity and new synaptic connection formation
- Research into neurodegenerative disease therapeutics (Alzheimer's, Parkinson's)
- Nootropic stacking for individuals seeking enhanced learning capacity
Choose Pinealon if...
- Neuroprotection against age-related cognitive decline and neurodegeneration
- Supporting serotonin production in aging individuals with diminished serotonergic function
- Bioregulatory approach to brain aging using Khavinson peptide methodology
- Complementing other neuroprotective peptides in comprehensive anti-aging protocols